BiotechTube

Olmesartan medoxomil + Irbesartan + Valsartan

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Nov 1, 2004 → Feb 1, 2005

NCT ID
NCT00185055

About Olmesartan medoxomil + Irbesartan + Valsartan

Olmesartan medoxomil + Irbesartan + Valsartan is a approved stage product being developed by Daiichi Sankyo for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT00185055. Target conditions include Healthy.

What happened to similar drugs?

20 of 20 similar drugs in Healthy were approved

Approved (20) Terminated (1) Active (0)
✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved
✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved
✅Perampanel 6 MGEisaiApproved
✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved
✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved
✅Listerine Clinical Solutions Teeth Strength + Listerine Total Care Zero Alcohol Mouthwash + Colgate Cavity Protection ToothpasteJohnson & JohnsonApproved
✅Colgate Cavity Protection Toothpaste + LISTERINE ZERO Alcohol Mouthwash COOL MINT + LISTERINE COOL MINT Antiseptic MouthwashJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00185055ApprovedCompleted

Competing Products

20 competing products in Healthy

See all competitors
ProductCompanyStageHype Score
AZD0837AstraZenecaPhase 1
29
ValsartanNovartisPhase 1
29
CSL112 + PlaceboCSLPhase 1
29
UT-15CUnited TherapeuticsPhase 1
26
VNA-318 + PlaceboBiotrialPhase 1
19
Open-label TRV734 125 mg + TRV734 blinded + Oxycodone IR 10 mg + PlaceboTrevenaPhase 1
19
TRV130 + Moxifloxacin + PlaceboTrevenaPhase 1
19
Radiolabeled TRV130TrevenaPhase 1
19
TRV130A + Dextrose in WaterTrevenaPhase 1
19
TRV734TrevenaPhase 1
19
ALT02 + EU-licensed Herceptin + US-licensed HerceptinAlteogenPhase 1
29
ENZ215 + EU Sourced Prolia + US Sourced ProliaAlkem LaboratoriesPhase 1
29
KPL-404Kiniksa PharmaceuticalsPhase 1
23
MORF-057 + Placebo for MORF-057Eli LillyPhase 1
29
Propranolol + PseudoephedrineEli LillyPre-clinical
26
LY2157299Eli LillyPhase 1
29
Lasmiditan + PlaceboEli LillyPhase 1
29
LY3015014 + PlaceboEli LillyPhase 1
29
LOXO-783Eli LillyPhase 1
29
LY2541546 - IV + LY2541546 - SC + PlaceboEli LillyPhase 1
29